drugset
Drugs / vesemnogene lantuparvovec
last change Oct 2025 re-read 3 minutes ago

vesemnogene lantuparvovec

Gene therapy (AAV / viral vector)

Developed for
spinal muscular atrophy
Investigated by
Lantu Biopharma

Trials 2

today NCT07265232 · Ph 3 NCT06288230 · Ph 1/2
202520262027202820292030
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT06288230 Oct 2024 → Oct 2027 expected spinal muscular atrophy Lantu Biopharma Active not recruiting No outcome recorded
Phase 31 trial
Phase 3 NCT07265232 Oct 2025 → Oct 2030 expected spinal muscular atrophy Lantu Biopharma Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as vesemnogene lantuparvovec ClinicalTrials.gov intervention name — accepted as the source's own label NCT06288230 ↗
1

NCT07265232 ↗
Modality Gene therapy (AAV / viral vector) “AAV-hSMN1 (Vesemnogene Lantuparvovec) Gene Therapy” NCT06288230 ↗